Literature DB >> 12234860

Use of fluoroquinolones in patients with chronic hepatitis C virus-induced liver failure.

H Kojima1, K D E Kaita, K Hawkins, J Uhanova, G Y Minuk.   

Abstract

Fluroquinolone antibiotics have been reported to have antiviral properties against RNA viruses, including hepatitis C virus (HCV). In the present study, five patients with advanced liver disease secondary to chronic HCV received 500 mg daily of oral ciprofloxacin for 30 days. Serum HCV-RNA levels and liver enzyme abnormalities remained largely unchanged. Thus, the role of fluoroquinolones as antiviral agents for chronic HCV in patients with advanced liver disease appears to be limited.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12234860      PMCID： PMC128783          DOI： 10.1128/AAC.46.10.3280-3282.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative.

Authors:  S Ikeda; M Yazawa; C Nishimura
Journal:  Antiviral Res       Date:  1987-10       Impact factor: 5.970

2.  Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration.

Authors:  M Komatsu; T Ishii; T Ono; T Hoshino; T Kuramitsu; T Goto; T Fujii; I Toyoshima; M Chiba; O Masamune
Journal:  Can J Gastroenterol       Date:  1997-09       Impact factor: 3.522

3.  Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin.

Authors:  B Campillo; C Dupeyron; J P Richardet; N Mangeney; G Leluan
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

4.  Fluoroquinolones protect the human lymphocyte CEM cell line from HIV-1-mediated cytotoxicity.

Authors:  J Nozaki-Renard; T Iino; Y Sato; Y Marumoto; G Ohta; M Furusawa
Journal:  Cell Struct Funct       Date:  1990-10       Impact factor: 2.212

Review 5.  Pathogenesis, natural history, treatment, and prevention of hepatitis C.

Authors:  T J Liang; B Rehermann; L B Seeff; J H Hoofnagle
Journal:  Ann Intern Med       Date:  2000-02-15       Impact factor: 25.391

6.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

Authors:  E J Heathcote; M L Shiffman; W G Cooksley; G M Dusheiko; S S Lee; L Balart; R Reindollar; R K Reddy; T L Wright; A Lin; J Hoffman; J De Pamphilis
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

7.  Inhibition of retrovirus RNA-dependent DNA polymerase by novobiocin and nalidixic acid.

Authors:  Y Sumiyoshi; T Nishikawa; T Watanabe; K Kano
Journal:  J Gen Virol       Date:  1983-10       Impact factor: 3.891

8.  Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study.

Authors:  M Tsutsumi; A Takada; S Takase; M Sawada
Journal:  J Gastroenterol Hepatol       Date:  1996-11       Impact factor: 4.029

9.  European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.

Authors:  C Féray; L Caccamo; G J Alexander; B Ducot; J Gugenheim; T Casanovas; C Loinaz; M Gigou; P Burra; L Barkholt; R Esteban; T Bizollon; J Lerut; A Minello-Franza; P H Bernard; K Nachbaur; D Botta-Fridlund; H Bismuth; S W Schalm; D Samuel
Journal:  Gastroenterology       Date:  1999-09       Impact factor: 22.682

10.  Effects of hepatic stimulator substance, herbal medicine, selenium/vitamin E, and ciprofloxacin on cirrhosis in the rat.

Authors:  M Zhang; G Song; G Y Minuk
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682
View more
  4 in total

1.  The altered expression of α1 and β3 subunits of the gamma-aminobutyric acid A receptor is related to the hepatitis C virus infection.

Authors:  M Sidorkiewicz; M Brocka; M Bronis; M Grek; B Jozwiak; A Piekarska; J Bartkowiak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-13       Impact factor: 3.267

Review 2.  Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

Authors:  A Dalhoff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-17       Impact factor: 3.267

3.  Old Drugs with New Tricks: Efficacy of Fluoroquinolones to Suppress Replication of Flaviviruses.

Authors:  Stacey L P Scroggs; Christy C Andrade; Ramesh Chinnasamy; Sasha R Azar; Erin E Schirtzinger; Erin I Garcia; Jeffrey B Arterburn; Kathryn A Hanley; Shannan L Rossi
Journal:  Viruses       Date:  2020-09-13       Impact factor: 5.048

4.  In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease.

Authors:  Rania Alaaeldin; Muhamad Mustafa; Gamal El-Din A Abuo-Rahma; Moustafa Fathy
Journal:  Fundam Clin Pharmacol       Date:  2021-07-30       Impact factor: 2.747
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.